Positive expectations of depressive patients in correlation with their course of treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028733

Enrollment

Registered

2022-05-05

Start date

2022-06-22

Completion date

Unknown

Last updated

2025-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

F32 F33

Interventions

Group 1: Patients with a depressive syndrome are asked several times about their symptoms, experience and expectations regarding their medication and treatment Experiment: within-subject design with

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Psychiatric disorder requiring treatment with depressive syndrome - Medical information and signed declaration of consent

Exclusion criteria

Exclusion criteria: - neurological disease - psychotic disorder - bipolar disorder in manic phase - addiction disorder

Design outcomes

Primary

Measure	Time frame
1. Change in mood recorded by VAS [time frame: baseline, before and after expectancy induction during experimental days, weekly survey during treatment] 2. Change in sum of depressive symptoms recorded by BDI-II [time frame: baseline, weekly survey during inpatient treatment, 12 weeks after treatment initiation]	—

Secondary

Measure	Time frame
1. Changes in positive and negative experience due to psychotherapy and medication recorded using GEEE [time frame: baseline, weekly survey during treatment, 12 weeks after treatment initiation]. 2. Changes in positive and negative expectation of antidepressant medication and psychotherapy recorded by GEEE [time frame: baseline, weekly survey during treatment, 12 weeks after treatment initiation]. 3. Prior experience with antidepressants and psychotherapy recorded via structured interview/GEEE [time frame: at inclusion]. 4. Recording of general complaints/side effects using GEEE [time frame: baseline, weekly survey during treatment, 12 weeks after treatment initiation] 5. Expectancy of treatment with nasal spray on experimental days recorded by GEEE [time frame: each time after expectancy induction on the experimantal days]. 6. Recognition rates during the emotion classification task [time frame: during the task on both experimental days]. 7. Experience through treatment with the nasal spray on the experimental days recorded using GEEE [time frame: at the end of the experimental days]. 8. Reaction times in cognitive control task [time frame: baseline]. 9. Recording of psychiatric disorders using MINI [time frame: baseline].	—

Measure

Time frame

1. Changes in positive and negative experience due to psychotherapy and medication recorded using GEEE [time frame: baseline, weekly survey during treatment, 12 weeks after treatment initiation]. 2. Changes in positive and negative expectation of antidepressant medication and psychotherapy recorded by GEEE [time frame: baseline, weekly survey during treatment, 12 weeks after treatment initiation]. 3. Prior experience with antidepressants and psychotherapy recorded via structured interview/GEEE [time frame: at inclusion]. 4. Recording of general complaints/side effects using GEEE [time frame: baseline, weekly survey during treatment, 12 weeks after treatment initiation] 5. Expectancy of treatment with nasal spray on experimental days recorded by GEEE [time frame: each time after expectancy induction on the experimantal days]. 6. Recognition rates during the emotion classification task [time frame: during the task on both experimental days]. 7. Experience through treatment with the nasal spray on the experimental days recorded using GEEE [time frame: at the end of the experimental days]. 8. Reaction times in cognitive control task [time frame: baseline]. 9. Recording of psychiatric disorders using MINI [time frame: baseline].

—

Countries

Germany

Contacts

Public ContactJonas Rauh

Universitätsklinikum Hamburg-Eppendorf

j.rauh@uke.de040741057186

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026